1
|
Darabi S, Elliott A, Braxton DR, Zeng J, Hodges K, Poorman K, Swensen J, Shanthappa BU, Hinton JP, Gibney GT, Moser J, Phung T, Atkins MB, In GK, Korn WM, Eisenberg BL, Demeure MJ. Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions. Cancers (Basel) 2022; 14:cancers14061505. [PMID: 35326655 PMCID: PMC8946593 DOI: 10.3390/cancers14061505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2022] [Revised: 03/08/2022] [Accepted: 03/10/2022] [Indexed: 11/24/2022] Open
Abstract
Simple Summary Malignant melanoma is a complex disease that is estimated to claim over 7000 lives in the United States in 2021. Although recent advances in genomic technology have helped with the identification of driver variants, molecular studies and clinical trials have often focused on prevalent alterations, such as the BRAF-V600E mutation. With the inclusion of whole transcriptome sequencing, molecular profiling of melanomas has identified gene fusions and revealed gene expression profiles that are consistent with the activation of signaling pathways by common driver mutations. Patients harboring such fusions may benefit from currently approved targeted therapies and should be considered in the design of future clinical trials to further personalize treatments for patients with malignant melanoma. Abstract Invasive melanoma is the deadliest type of skin cancer, with 101,110 expected cases to be diagnosed in 2021. Recurrent BRAF and NRAS mutations are well documented in melanoma. Biologic implications of gene fusions and the efficacy of therapeutically targeting them remains unknown. Retrospective review of patient samples that underwent next-generation sequencing of the exons of 592 cancer-relevant genes and whole transcriptome sequencing for the detection of gene fusion events and gene expression profiling. Expression of PDL1 and ERK1/2 was assessed by immunohistochemistry (IHC). There were 33 (2.6%) cases with oncogenic fusions (14 novel), involving BRAF, RAF1, PRKCA, TERT, AXL, and FGFR3. MAPK pathway-associated genes were over-expressed in BRAF and RAF1 fusion-positive tumors in absence of other driver alterations. Increased expression in tumors with PRKCA and TERT fusions was concurrent with MAPK pathway alterations. For a subset of samples with available tissue, increased phosphorylation of ERK1/2 was observed in BRAF, RAF1, and PRKCA fusion-positive tumors. Oncogenic gene fusions are associated with transcriptional activation of the MAPK pathway, suggesting they could be therapeutic targets with available inhibitors. Additional analyses to fully characterize the oncogenic effects of these fusions may support biomarker driven clinical trials.
Collapse
Affiliation(s)
- Sourat Darabi
- Hoag Family Cancer Institute, Newport Beach, CA 92663, USA; (D.R.B.); (B.L.E.); (M.J.D.)
- Correspondence:
| | - Andrew Elliott
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - David R. Braxton
- Hoag Family Cancer Institute, Newport Beach, CA 92663, USA; (D.R.B.); (B.L.E.); (M.J.D.)
| | - Jia Zeng
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - Kurt Hodges
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - Kelsey Poorman
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - Jeff Swensen
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - Basavaraja U. Shanthappa
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - James P. Hinton
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - Geoffrey T. Gibney
- Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC 20007, USA; (G.T.G.); (M.B.A.)
| | - Justin Moser
- Honor Health Research Institute, Scottsdale, AZ 85258, USA;
| | - Thuy Phung
- Department of Pathology, University of South Alabama, Mobile, AL 36617, USA;
| | - Michael B. Atkins
- Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC 20007, USA; (G.T.G.); (M.B.A.)
| | - Gino K. In
- Division of Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA;
| | - Wolfgang M. Korn
- Caris Life Sciences, Phoenix, AZ 85040, USA; (A.E.); (J.Z.); (K.H.); (K.P.); (J.S.); (B.U.S.); (J.P.H.); (W.M.K.)
| | - Burton L. Eisenberg
- Hoag Family Cancer Institute, Newport Beach, CA 92663, USA; (D.R.B.); (B.L.E.); (M.J.D.)
- Division of Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA;
| | - Michael J. Demeure
- Hoag Family Cancer Institute, Newport Beach, CA 92663, USA; (D.R.B.); (B.L.E.); (M.J.D.)
- Translational Genomics Research Institution, Phoenix, AZ 85004, USA
| |
Collapse
|
2
|
Smalley M, Alam N, Murmu N, Somashekhar S, Ulaganathan B, Thayakumar A, Maciejko L, Ganesh J, Lawson M, Gertje H, Shanthappa BU, Goldman A. Abstract P6-07-03: A live tissue platform allows dynamic measurement of neovascularization and prediction of clinical response in human breast cancer samples, ex vivo. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-07-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Outgrowth of new blood vessels (neovascularization) allows tumors to supply themselves with oxygen and nutrients, and to rapidly metastasize throughout the body. Triple negative breast cancer (TNBC) is particularly susceptible to neovascularization. However, success with anti-angiogenics is highly variable and often patient-specific. This is particularly true as anti-angiogenics are being combined with immunotherapies. Thus, there is a huge unmet need for clinicians to test and predict clinical efficacy of anti-angiogenics at the individual patient level, prior to treatment.
Methods: Here, we characterize a patient-autologous, ex-vivo tumor model, termed CANscript, as a platform to study the intratumor microvascular density (iMVD) of breast cancer samples (N=15). To profile iMVD we used immunohistochemical (IHC) analysis of CD34, an early biomarker of neovascularization. We then introduced anticancer and anti-angiogenic agents (e.g. Avastin) for 72 hours, and subsequently quantified phenotypic response to drugs by testing viability, cell death, proliferation and morphology. These quantitative data were then fed into a machine learning algorithm that provides a clinical response prediction (M-Score).
Results: We determined that ex-vivo culture reliably retains baseline heterogeneity of iMVD based on expression of CD34+ nodes per visual field by IHC. Furthermore, we show that anticancer and anti-angiogenic agents will dynamically alter iMVD, ex-vivo, in a patient-specific manner. Finally, we show that prediction of clinical response using the 'M-Score' algorithm associates with diminished expression of CD34 per visual field of IHC after drug pressure.
Summary: Neovascularization and iMVD are features of aggressive cancers, such as TNBC. CANscript provides a rapid assessment of clinical response to anticancer drugs, many of which induce their antitumor effect by targeting the tumor vasculature. We show that pharmacodynamics of antiangiogenics can be captured during acute ex-vivo culture under drug pressure, which associate to clinical response prediction. Therefore, we highlight the ability of CANscript as a platform to predict clinical response to anti-angiogenic drugs, and may therefore be a logical 'testing ground' to predict clinical efficacy of antiangiogenic drugs combined with immunotherapies.
Citation Format: Smalley M, Alam N, Murmu N, Somashekhar S, Ulaganathan B, Thayakumar A, Maciejko L, Ganesh J, Lawson M, Gertje H, Shanthappa BU, Goldman A. A live tissue platform allows dynamic measurement of neovascularization and prediction of clinical response in human breast cancer samples, ex vivo [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-07-03.
Collapse
Affiliation(s)
- M Smalley
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - N Alam
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - N Murmu
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - S Somashekhar
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - B Ulaganathan
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - A Thayakumar
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - L Maciejko
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - J Ganesh
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - M Lawson
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - H Gertje
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - BU Shanthappa
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - A Goldman
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| |
Collapse
|
3
|
Smalley M, Shanthappa BU, Gertje H, Lawson M, Ulaganathan B, Thayakumar A, Maciejko L, Radhakrishnan P, Biswas M, Thiyagarajan S, Majumder B, Gopinath KS, K GB, Goldman A. Abstract P5-11-04: Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-11-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Predicting patient-specific clinical response to anticancer therapy is the holy grail of treatment-selection. It is now clear that response or resistance to therapy depends on the heterogeneous tumor microenvironment, which is comprised of malignant cells, normal stroma, soluble ligands, and tumor-immune contexture; attributes that are unique to each individual patient. This is particularly true for emerging anticancer drugs, such as immune checkpoint inhibitors, which recalibrate the body's own immune defense largely by modulating exhaustion of cytotoxic lymphocytes including T cells and natural killer (NK) cells. However, clinical response to therapy varies enormously. There is a critical gap in our understanding for the mechanisms that drive response or resistance to conventional drugs and immunotherapies at the individual patient level.
Methods: Here, we used a fully patient-autologous, clinically-validated ex-vivo tumor model that recreates and preserves the native, patient tumor microenvironment (CANscriptTM), which incorporates an algorithm-driven method to predict clinical response to therapy (M-Score). Utilizing tissue from patients diagnosed with luminal, HER2 positive, and triple-negative (ER- PR- HER2-) breast cancers (N=10), we studied phenotypic alterations to the tumor-immune contexture under pressure of conventional standard-of-care regimens and immunotherapies including immune-checkpoint inhibitors, ex-vivo. To do this, we used a comprehensive panel of immunological assays to evaluate changes in cytotoxic lymphocytes by flow cytometry and multiplex immunohistochemistry (i.e. CD56, MHC class 1A/B, NKG2D/C, CD8, CD3, PD-1, CTLA-4, TIM-3, LAG-3, 4-1BB, granzyme A/B). In addition, we used multiplex cytokine analysis to study the soluble components of the tumor microenvironment.
Results: We identified that tumor response, predicted by M-Score, correlates to increased infiltration of NK cells, which associated a pro-inflammatory cytokine signature from the tumor microenvironment. Interestingly, these evidences were concordant with induction of the tumor-expressing biomarker MICA/B, which is known to attract and recruit active NK cells. Furthermore, we determined that therapy-induced expression of protein biomarkers associated with NK cell exhaustion inversely correlated to the expression of cytotoxic granzyme B in the tumor microenvironment.
Conclusions: Taken together, these data demonstrate an integral role that NK cells contribute to the antitumor effect of therapy including conventional and immuno-modulatory drugs. It further demonstrates how a novel ex-vivo platform can be harnessed to study the mechanisms of response and resistance, which couldn't otherwise be known in a drug naïve state. Such an advance in our preclinical methods to study anticancer drugs at the individual patient level can help guide treatment decisions for clinicians while simultaneously functioning as a platform to study clinical efficacy of novel and emerging agents.
Citation Format: Smalley M, Shanthappa BU, Gertje H, Lawson M, Ulaganathan B, Thayakumar A, Maciejko L, Radhakrishnan P, Biswas M, Thiyagarajan S, Majumder B, Gopinath KS, K GB, Goldman A. Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-11-04.
Collapse
Affiliation(s)
- M Smalley
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - BU Shanthappa
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - H Gertje
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - M Lawson
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - B Ulaganathan
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - A Thayakumar
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - L Maciejko
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - P Radhakrishnan
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - M Biswas
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - S Thiyagarajan
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - B Majumder
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - KS Gopinath
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - GB K
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - A Goldman
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| |
Collapse
|
4
|
Radhakrishnan P, Goldman A, Ulaganathan B, Thaya Kumar A, Maciejko L, Gertje H, Shanthappa BU, Mehrotra DGG, Biswas M, Thiyagarajan S, Majumder B. Predicting tumor-immune response to checkpoint inhibitors using a novel patient-derived live tumor explant model. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e20035] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20035 Background: Immunotherapy has emerged as a powerful treatment paradigm wherein therapies primarily target immune components. For example, blockade of PD-1 and PD-L1 offers effective treatment options for patients with aggressive tumors such as head and neck squamous cell carcinoma (HNSCC) and in non-small cell lung carcinoma (NSCLC). However, clinical responses to immotherapy vary widely among patients. There is an unmet need to understand these disparities at the individual patient level. Rationally combining checkpoint inhibitors may address many of these underlying challenges. Methods: Here, we describe a patient-derived ex-vivo platform technology CANscript™, which captures the 3D profiles of native tumor microenvironment by incorporating tumor tissue, autologous immune cells, and immune-targeted agents. Utilizing late stage HNSCC and NSCLC patient tumors we interrogated the phenotypic changes in the tumor-immune contexture in response to standard-of-care agents, PD-1 and PD-L1 inhibitors. Flow cytometry and immunohistochemistry profiling of CD8, CD45, FOXP3, CXCR4, CD68, PDL1, PD1), cytokine profile (IL6, IL8, IFN-g, IL12 and others), and tumor proliferation/apoptosis were measured. Results: The data suggest that PD-1 and PD-L1 blockade induced patient-specific response, which was characterized by differential distribution and infiltration of CD8+ and CD4+ lymphocytes, distinct patterning of cytokines linked to functional dysregulation, and changes in tumor proliferation and apoptosis. Interestingly, the data demonstrated unique immune signatures associated with single agent vs. combination therapy that imply functionally distinct mechanisms of orchestration of response. Conclusions: Our data highlights the translational underpinnings of of CANScript™ as an ex vivo platform for predicting patient driven therapeutic response of immune checkpoint inhibitors where distinct tumor-immune networks influence clinical response to therapy. Information obtained from this study can re-shape our understanding of patient selection and rational combinations for novel immune checkpoint inhibitors.
Collapse
|
5
|
Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, Brijwani N, Pinto DD, Prasath A, Shanthappa BU, Thayakumar A, Surendran R, Babu GK, Shenoy AM, Kuriakose MA, Bergthold G, Horowitz P, Loda M, Beroukhim R, Agarwal S, Sengupta S, Sundaram M, Majumder PK. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun 2015; 6:6169. [PMID: 25721094 PMCID: PMC4351621 DOI: 10.1038/ncomms7169] [Citation(s) in RCA: 215] [Impact Index Per Article: 23.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2014] [Accepted: 12/22/2014] [Indexed: 12/19/2022] Open
Abstract
Predicting clinical response to anticancer drugs remains a major challenge in cancer treatment. Emerging reports indicate that the tumour microenvironment and heterogeneity can limit the predictive power of current biomarker-guided strategies for chemotherapy. Here we report the engineering of personalized tumour ecosystems that contextually conserve the tumour heterogeneity, and phenocopy the tumour microenvironment using tumour explants maintained in defined tumour grade-matched matrix support and autologous patient serum. The functional response of tumour ecosystems, engineered from 109 patients, to anticancer drugs, together with the corresponding clinical outcomes, is used to train a machine learning algorithm; the learned model is then applied to predict the clinical response in an independent validation group of 55 patients, where we achieve 100% sensitivity in predictions while keeping specificity in a desired high range. The tumour ecosystem and algorithm, together termed the CANScript technology, can emerge as a powerful platform for enabling personalized medicine.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Govind K Babu
- Kidwai Memorial Institute of Oncology, Bangalore 560030, India
| | - Ashok M Shenoy
- Kidwai Memorial Institute of Oncology, Bangalore 560030, India
| | | | - Guillaume Bergthold
- The Broad Institute of The Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA
| | - Peleg Horowitz
- 1] The Broad Institute of The Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA [2] Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA [3] Children's Hospital, Boston, Massachusetts 02115, USA
| | - Massimo Loda
- 1] The Broad Institute of The Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA [2] Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Rameen Beroukhim
- 1] Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA [2] Children's Hospital, Boston, Massachusetts 02115, USA
| | | | - Shiladitya Sengupta
- 1] Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA [2] India Innovation Research Center, New Delhi 110092, India [3] Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts 02139, USA
| | | | - Pradip K Majumder
- 1] Mitra Biotech, Bangalore 560099, India [2] India Innovation Research Center, New Delhi 110092, India
| |
Collapse
|